Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to -$93.7 million.

  • Trinity Biotech's Retained Earnings fell 6205.98% to -$93.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$93.7 million, marking a year-over-year decrease of 6205.98%. This contributed to the annual value of -$79.1 million for FY2024, which is 6264.49% down from last year.
  • Latest data reveals that Trinity Biotech reported Retained Earnings of -$93.7 million as of Q2 2025, which was down 6205.98% from -$79.1 million recorded in Q4 2024.
  • Trinity Biotech's 5-year Retained Earnings high stood at $13.7 million for Q3 2021, and its period low was -$93.7 million during Q2 2025.
  • For the 5-year period, Trinity Biotech's Retained Earnings averaged around -$28.8 million, with its median value being -$31.1 million (2023).
  • Per our database at Business Quant, Trinity Biotech's Retained Earnings soared by 4758.36% in 2021 and then tumbled by 18329565.22% in 2023.
  • Quarter analysis of 5 years shows Trinity Biotech's Retained Earnings stood at $23000.0 in 2021, then tumbled by 116165.22% to -$26.7 million in 2022, then plummeted by 82.22% to -$48.6 million in 2023, then crashed by 62.64% to -$79.1 million in 2024, then dropped by 18.38% to -$93.7 million in 2025.
  • Its Retained Earnings was -$93.7 million in Q2 2025, compared to -$79.1 million in Q4 2024 and -$62.3 million in Q3 2024.